(Q34173557)

English

Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Debbie C Koay

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Cynthia Zerillo

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Murli Narayan

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Lyndsay N Harris

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Michael P DiGiovanna

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

9 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Breast Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

R62

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Estrogen to antiestrogen with a single methylene group resulting in an unusual steroidal selective estrogen receptor modulator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

How retinoids regulate breast cancer cell proliferation and apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Synergistic interactions between tamoxifen and trastuzumab (Herceptin).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

HER2/neu uses Akt to suppress retinoic acid response element binding activity in MDA-MB-453 breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Human breast cancer cells and normal mammary epithelial cells: retinol metabolism and growth inhibition by the retinol metabolite 4-oxoretinol.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Pharmacokinetics and clinical impact of all- trans retinoic acid in metastatic breast cancer: a phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

A decade of molecular biology of retinoic acid receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

The RXR heterodimers and orphan receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Vertebrate receptors: molecular biology, dimerization and response elements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Staining of DNA in live and fixed cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Phase II trial of 13-cis-retinoic acid in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Control of human breast cancer by estrogen, growth factors, and oncogenes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Responses to retinoic acid of tamoxifen-sensitive and -resistant sublines of human breast cancer cell line MCF-7

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Isolation of two human tumor epithelial cell lines from solid breast carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 July 2018

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

https://api.crossref.org/works/10.1186%2FBCR2625

21 January 2018

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1186%2FBCR2625

21 January 2018

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial

1 reference

https://api.crossref.org/works/10.1186%2FBCR2625

21 January 2018

A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2FBCR2625

21 January 2018

Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells

1 reference

https://api.crossref.org/works/10.1186%2FBCR2625

21 January 2018

Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene.

1 reference

https://api.crossref.org/works/10.1186%2FBCR2625

21 January 2018

Modulation of membrane fluidity and lipidic metabolism in transformed rat fibroblasts induced by the sesquiterpenic hormone farnesylacetone

1 reference

https://api.crossref.org/works/10.1186%2FBCR2625

21 January 2018

Heregulin and retinoids synergistically induce branching morphogenesis of breast cancer cells cultivated in 3D collagen gels

1 reference

https://api.crossref.org/works/10.1186%2FBCR2625

21 January 2018

Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2FBCR2625

21 January 2018

Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer

1 reference

https://api.crossref.org/works/10.1186%2FBCR2625

21 January 2018

The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 October 2018

Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 October 2018

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 October 2018

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 October 2018

Activation of retinoic acid receptor alpha is sufficient for full induction of retinoid responses in SK-BR-3 and T47D human breast cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 October 2018

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2949655

28 October 2018

Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiestrogenic effects of all-trans-retinoic acid and 1,25-dihydroxyvitamin D3 in breast cancer cells occur at the estrogen response element level but through different molecular mechanisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-beta, retinoids, and tamoxifen in the treatment of metastatic breast cancer: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tyrosine kinase signaling pathways control the expression of retinoic acid receptor-alpha in SK-BR-3 breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retinoids control the expression of c-erbB receptors in breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of c-erbB-4/HER4 is regulated in T47D breast carcinoma cells by retinoids and vitamin D3

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tamoxifen and fenretinide in women with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Involvement of nuclear steroid/thyroid/retinoid receptors and of protein kinases in the regulation of growth and of c-erbB and retinoic acid receptor expression in MCF-7 breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages--immunohistochemical study of 107 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/BCR2625

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34173557&oldid=2196346176"